CytoReason Secures $80M from OurCrowd, NVIDIA, Pfizer, and Thermo Fisher Scientific to Scale Its AI Disease Models and Establish US Hub in Cambridge, Massachusetts
CytoReason and the Crohn’s & Colitis Foundation Forge Groundbreaking Data Collaboration to Advance IBD Research
CytoReason to License Its IBD Disease Model to Sanofi in Expanded Multiyear, Multimillion Dollar Deal
Poolbeg Pharma reaches R&D milestone as partner CytoReason completes AI influenza disease model
CytoReason Announces Expanded Collaboration Deal with Pfizer to Deliver AI for Drug Discovery and Development
CytoReason Expands Its Reach in Asia, Forging Commercial Alliance with Helixrus to Leverage Machine Learning in Drug Development for Korean Drugmakers
CytoReason and Pfizer Extend Collaboration to Leverage Machine Learning in Drug Development
Cytoreason and Summit Pharmaceuticals International forge commercial alliance to bring CytoReason’s machine learning model of the immune system for drug discovery & development to Japanese drug makers
CytoReason Collaborates with Sanofi, Using its AI Technology to Gain Better Understanding of Disease Mechanisms
CytoReason Announces Collaboration with Ferring to Identify Novel Therapeutic Targets in Inflammatory Bowel Disease Using AI Technology
